Immupharma (IMM)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

2.20p
   
  • Change Today:
      0.020p
  • 52 Week High: 3.42
  • 52 Week Low: 0.85
  • Currency: UK Pounds
  • Shares Issued: 416.44m
  • Volume: 91,450
  • Market Cap: £9.16m
  • RiskGrade: 328

Dividends

Year End Type Amount Payment Date Ex-Div Date Record Date
31-Dec-18 Interim 00.00      
  Final 00.00      

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Historical interim dividends and record dates not previously collected

Note 4: Forecast figures based on normalised accounts.

 

IFRS Changes - Find Out More

Find out about IFRS and how this affects the financial infomation for all UK companies.

Immupharma Market Data

Currency UK Pounds
Share Price 2.20p
Change Today 0.020p
% Change 0.92 %
52 Week High 3.42
52 Week Low 0.85
Volume 91,450
Shares Issued 416.44m
Market Cap £9.16m
RiskGrade 328

Immupharma Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
64.73% below the market average64.73% below the market average64.73% below the market average64.73% below the market average64.73% below the market average
13.21% below the sector average13.21% below the sector average13.21% below the sector average13.21% below the sector average13.21% below the sector average
Price Trend
22.82% below the market average22.82% below the market average22.82% below the market average22.82% below the market average22.82% below the market average
43.86% above the sector average43.86% above the sector average43.86% above the sector average43.86% above the sector average43.86% above the sector average
Income Not Available
Growth Not Available

Immupharma Dividends

No dividends found

Trades for 24-Apr-2024

Time Volume / Share Price
10:13 31,269 @ 2.11p
09:09 400 @ 2.11p
08:54 15,000 @ 2.19p
08:54 18,381 @ 2.20p
08:54 25,000 @ 2.19p

Immupharma Key Personnel

CEO Timothy Paul McCarthy

Top of Page